Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals, Inc. reported higher revenue and a reduced net loss for the quarter ended June 30, 2026. Total revenues were $173.9 million versus $102.7 million a year earlier, driven entirely by XDEMVY product sales. Net loss for the quarter narrowed to $18.6 million, or $0.43 per share, compared with $20.3 million, or $0.48 per share.
For the first six months of 2026, revenue reached $336.0 million, including $319.3 million of product sales and $16.7 million of license and collaboration revenue. Operating expenses grew as Tarsus expanded R&D and commercial operations, but loss from operations improved to $26.0 million from $48.5 million.
Tarsus generated $36.6 million of net cash from operating activities in the first half of 2026, compared with $50.0 million of cash used a year earlier. Cash, cash equivalents, restricted cash and marketable securities totaled over $451 million, and management estimates existing capital resources will cover at least 12 months of projected needs. The company remains heavily dependent on XDEMVY for Demodex blepharitis and continues to invest in pipeline candidates TP-04 and TP-05 while highlighting significant commercialization, market, supply, and clinical development risks.
Tarsus Pharmaceuticals reported strong Q2 2026 performance, with XDEMVY net product sales of $173.9 million, an increase of more than 69% year-over-year. For the first half of 2026, XDEMVY product sales reached $319.3 million and license and collaboration revenue totaled $16.7 million from a China out-license milestone.
Operating expenses rose as the company invested in commercialization and pipeline programs: Q2 R&D was $31.0 million and SG&A was $150.7 million. Net loss was $18.6 million for Q2 and $25.5 million year-to-date, both lower than in 2025. Cash, cash equivalents and marketable securities were $449.7 million as of June 30, 2026.
Tarsus completed the acquisition of iRenix Medical, gaining IRX-101 in retina, and entered into an agreement to acquire Alkeus Pharmaceuticals and ALK-001. It also priced a $125 million private placement and advanced multiple clinical programs, with several Phase 2 and Phase 3 readouts expected beginning in 2027.
Tarsus Pharmaceuticals, Inc. agreed on August 5, 2026 to a private investment in public equity with existing and new healthcare investors, selling 2,098,519 shares of common stock at $56.00 per share and issuing pre-funded warrants to purchase up to 133,625 shares at $55.9999 per warrant, with a $0.0001 per-share exercise price. The financing is expected to close on August 7, 2026, subject to customary conditions, and is expected to generate approximately $125.0 million in gross proceeds before fees and any warrant-exercise proceeds. Tarsus plans to use net proceeds for clinical development, commercial activities and other general corporate purposes.
The pre-funded warrants are exercisable at any time, do not expire until fully exercised, and limit each holder’s ownership to 4.99% (or 9.99% if elected) of outstanding common stock after exercise. Tarsus agreed to a 90-day restriction on additional equity offerings, and its directors and officers entered 90-day lock-ups. A Registration Rights Agreement commits Tarsus to register the resale of the investors’ securities on a timeline linked to its pending acquisition of Alkeus Pharmaceuticals, with Tarsus bearing related registration expenses. Barclays acts as lead placement agent, with BofA Securities and William Blair as co-placement agents, and the securities are being sold under Section 4(a)(2) of the Securities Act.
Tarsus Pharmaceuticals, Inc. agreed to acquire Alkeus Pharmaceuticals through a merger that will make Alkeus a wholly owned subsidiary. The pending deal includes approximately $450 million in up-front consideration, consisting of $270 million in cash and $180 million of common stock valued at $61.38 per share, plus up to $350 million in additional milestone payments tied to U.S. regulatory approval and first commercial sale of an Alkeus product. Alkeus equityholders are also entitled to tiered payments based on worldwide net sales of gildeuretinol. Closing is subject to customary conditions, including expiration of the Hart-Scott-Rodino waiting period, and is expected in 2026, with an outside date that can be extended to January 31, 2027.
The acquisition adds gildeuretinol (ALK-001), an oral Phase 3 candidate for Stargardt disease, to Tarsus’ retina portfolio. Prior studies in more than 400 individuals showed a 29.5% slower growth rate of atrophic lesions and an 87% lower risk of significant low light visual acuity loss versus control, with some patients treated for over seven years. Top-line data from the ongoing NORTHSTAR Phase 3 trial in approximately 230 patients are expected in the second half of 2029. Tarsus also agreed to register the resale of stock issued in the transaction and to lock up certain Alkeus holders for two months after closing.
Tarsus Pharmaceuticals, Inc. reported a leadership change in its commercial organization. On July 13, 2026, the company announced that Aziz Mottiwala will leave his role as Chief Commercial Officer and end his employment with Tarsus on July 15, 2026.
The company stated that Mottiwala is departing to pursue a new opportunity as Chief Executive Officer of a public medical device company. The report is made as a departure of a certain officer under the disclosure requirements for corporate officers.
Tarsus Pharmaceuticals completed the acquisition of privately held iRenix Medical, bringing in late-stage ocular antiseptic candidate IRX-101. The upfront consideration totals approximately $75 million, consisting of $37.5 million in cash and 607,093 Tarsus common shares, valued at about $37.5 million.
iRenix equityholders may receive up to an additional $490 million in regulatory and commercial milestone payments, plus low-to-mid single-digit revenue sharing on future net sales of certain products. IRX-101, a stable aqueous chlorine dioxide solution, showed statistically significant ~50% relative reduction in post-procedural pain and ~25% reduction in corneal staining versus povidone-iodine in a 154-patient Phase 2b/3 RELIEF trial.
With FDA-aligned feedback, Tarsus plans a Phase 3 study of IRX-101 versus povidone-iodine, expected to begin enrolling in the first half of 2027 with results anticipated in 2028, supporting its strategy to expand leadership in eye care beyond its approved product XDEMVY.
Goodrich Katherine reported acquisition or exercise transactions in this Form 4 filing.
Tarsus Pharmaceuticals director Katherine Goodrich received new equity awards as part of her non-employee director compensation. She was granted 2,417 restricted stock units, each representing one share of common stock, and stock options for 3,837 shares with a strike price of $64.34. Both the RSUs and options vest in full one year after the June 25, 2026 grant date, contingent on her continued board service.
Tarsus Pharmaceuticals director Andrew D. Goldberg received new equity awards as part of his compensation for serving as a non-employee director. He was granted 2,417 Restricted Stock Units, each representing a contingent right to receive one share of Tarsus common stock. He also received a stock option covering 3,837 shares of common stock at an exercise price of $64.34 per share. Both the RSUs and the option were granted in connection with the company’s 2026 annual meeting of stockholders and will vest in full on the one-year anniversary of the grant date, subject to his continuous board service.
Tarsus Pharmaceuticals director Morrison Scott W received new equity awards tied to his service as a non-employee director. He was granted 2,417 Restricted Stock Units, each representing a right to receive one share of common stock, and 3,837 stock options to buy common stock at an exercise price of $64.34 per share.
Both the RSUs and options were granted as of the company’s 2026 annual meeting of stockholders and will vest in full on the one-year anniversary of the grant date, subject to his continuous service. Following these grants, his reported holdings in these specific RSU and option awards are 2,417 and 3,837 units, respectively.
Tarsus Pharmaceuticals, Inc. reported that director Bhaskar Chaudhuri received new equity awards as part of his compensation for serving as a non-employee director at the company’s 2026 annual meeting of stockholders. He was granted 2,417 Restricted Stock Units, each representing one share of common stock, and a stock option for 3,837 shares of common stock at an exercise price of $64.34 per share. Both the RSUs and the option vest in full on the one-year anniversary of the June 25, 2026 grant date, subject to his continuous service on the board.